During the development of lymphocytes, expression of the Ig genes is strictly regulated in a tissuespecific manner and in a time-ordered fashion. We have previously shown that the PU. 
Introduction
Pluripotent bone marrow stem cells differentiate into eight distinct cell lineages in mammalian hematopoiesis. Molecular mechanisms underlying the lineage commitment of stem cells are still largely unknown. It is generally accepted that the process is regulated by signals from stroma cells and by hematopoietic transcription factors. They include GATA-1 for red blood cell maturation (1, 2) ; Ikaros for development of lymphocytes, NK cells and neutrophils (3, 4) ; and Oct-2 for T cell-independent B cell activation and maturation (5, 6) .
During the development of lymphocytes, expression of antigen receptor genes is regulated in a cell-type-specific manner. In the Igκ gene, two enhancer regions, the intron enhancer (E κ ) and the 3Ј-enhancer (κE3Ј), play crucial roles in the developmentally controlled expression (7) (8) (9) (10) ). An Ets family protein, PU.1, has been shown to bind to the κE3Ј and enhance the transcription of the Igκ gene (11) . Using transgenic substrates, we have previously shown that the Correspondence to: H. Sakano Transmitting editor: K. Okumura Received 1 April 1999, accepted 13 May 1999 PU.1 binding motif in the κE3Ј is a cis-acting DNA element responsible for the negative control of V κ -J κ joining (12, 13) . However, the PU.1 protein itself may not be the recombinational repressor, because PU.1 is expressed in all of B cell developmental stages. We assume that a novel Ets family protein other than PU.1 may be involved in the recombinational regulation. In order to isolate the PU.1-related protein, we have screened cDNA libraries with the yeast one-hybrid system using the κE3Ј sequence as a probe. Here we report a novel PU.1-related factor, Prf, which is specifically expressed in restricted stages of B cell development.
Methods

cDNA library construction and yeast one-hybrid screening
A murine thymus cDNA library was constructed with oligo(dT) [12] [13] [14] [15] [16] [17] [18] and random hexameric primers (SuperScript Choice System for cDNA Synthesis; Gibco/BRL, Gaithersburg, MD) in a plasmid vector pGAD424 (Clontech, Palo Alto, CA), using poly(A) ϩ RNA prepared from newborn thymi of BALB/c mice. Bait plasmids, pHISi-PU and pLacZi-PU, were constructed with synthetic DNA oligomers containing three repeats of the PU.1-NF-EM5 binding region sequences of the κE3Ј, TTTGAGGAACTGAAAACAG (11) . To obtain a yeast reporter strain YMPU3i3, the bait plasmids were linearized and integrated into the yeast genome of a strain YM4271 by homologous recombination.
Yeast one-hybrid screening with the thymus cDNA library was carried out on His -, Ura -, SD plates supplemented with 25 mM 3-amino-1,2,4-triazole (14) .
In vitro expression and gel-shift assay For in vitro expression, prf cDNA of 729 bp was subcloned into a pBluescript vector (Stratagene, La Jolla, CA). RNA was translated from the recombinant pBluescript plasmid with T3 RNA polymerase. In vitro translations were performed with an aliquot of in vitro synthesized RNA (0.5 µg) preheated at 65°C for 10 min and 33 µl of nuclease-treated rabbit reticulocyte lysate (Promega, Madison, WI) with or without 20 µCi of [ 35 S] methionine. Translation reactions were carried out in a 50 µl reaction mixture at 30°C for 90 min.
For the gel-shift assay, Prf protein (2 µl of translation mixture) was incubated with 10,000 c.p.m. of 32 P-labeled doublestranded oligonucleotide probes in 20 µl of reaction mixture containing 25 mM NaCl, 100 µg/ml poly(dI;dC), 50 µg/ml of denatured and non-denatured salmon sperm DNA, 0.25 mg/ml BSA, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA and 1 mM dithiothreitol at 4°C for 30 min. Samples were loaded on 5% polyacrylamide gels (29:1, acrylamide:bisacrylamide) and electrophoresed in 0.25ϫTBE (1ϫTBE is 0.09 M Tris, 0.09 M boric acid and 0.005 M EDTA). Oligonucleotides for probes were synthesized according to the putative PU.1 binding sites. 
Cell sorting and RT-PCR analysis
To isolate Ig -B (pro-and pre-B) cells (NK1.1 -, B220 ϩ , HSA ϩ , Ig -, CD23 -) and immature B cells (NK1.1 -, B220 ϩ , HSA ϩ , Ig ϩ ), bone marrow cells from C57BL/6 mice were stained with biotinylated anti-NK1.1 mAb, allophycocyanin (APC)-coupled anti-B220 mAb, phycoerythrin (PE)-conjugated anti-HSA mAb and FITC-conjugated anti-IgM, anti-IgD and anti-CD23 mAb, followed by incubation with Texas Red-coupled streptavidin. Dead cells were discriminated by uptake of propidium iodide, and viable cells were sorted under the forward-and sidescatter lymphocyte gate on a FACS Vantage (Becton Dickinson, Mountain View, CA). Circulating B cells in the bone marrow were discriminated by the expression of low levels of HSA (HSA dull ) from immature B cells (HSA ϩ ) in FACS sorting.
To purify splenic B cells (B220 ϩ , Thy-1 -) and splenic T cells (B220 -, Thy-1 ϩ ), splenocytes were stained and sorted with APC-coupled anti-B220 mAb and PE-conjugated anti-Thy-1 mAb. For the separation of thymic CD3 lo (Thy-1 ϩ , CD3 lo ), thymic CD3 hi (Thy-1 ϩ , CD3 hi ), thymic Thy-1 -(Thy-1 -, CD3 hi , B220 -) and thymic B220 ϩ cells (Thy-1 dull , CD3 lo , B220 ϩ ), thymocytes were stained with PE-conjugated anti-Thy-1 mAb, FITC-conjugated anti-CD3 mAb and APC-coupled anti-B220 mAb.
To isolate pro-B and pre-B cells, non-B-lineage cells were first depleted from bone marrow cells using MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) with the following antibodies: anti-NK1.1 mAb, anti-CD5 mAb, anti-Gr-1 mAb, TER119 and anti-Thy1 mAb. The bone marrow B lineage cells were stained with the following antibodies and then stained with Texas Red-coupled streptavidin: biotinylated anti-IgM, anti-IgD and anti-CD23 mAb; APC-coupled anti-B220 mAb; PE-conjugated anti-HSA mAb; and FITC-conjugated anti-CD43 mAb. All antibodies for staining were purchased from PharMingen (San Diego, CA).
Total RNAs were prepared from 5ϫ10 4 sorted cells using the RNeasy Mini-kit (Qiagen, Hilden, Germany) according to the manufacturer's instruction. cDNA was made from total RNA samples with SuperScript II reverse transcriptase (Gibco/ BRL) in a 10 µl scale. Reverse transcriptase reaction products were subjected to 40 cycles of denaturation at 94°C for 30 s, primer annealing at 53°C for 1 min and primer extension at 72°C for 1.5 min with AmpliTaq Gold (Perkin-Elmer, Norwalk, CT). PCR products were separated in 1.5% agarose gels and either stained with ethidium bromide or transferred to Hybond-N ϩ membrane (Amersham, Pharmacia, Uppsala, Sweden) and subjected to Southern blotting. Hybridization was performed with the full-length prf coding sequence as a probe. Nucleotide sequences of a primer pair used for amplification of prf fragments are: forward primer, 5Ј-CGAATTCCATGACTT-GTTGTATTG-3Ј; reverse primer, 5Ј-TCTCGAGTTTTGTGACA-GACACTA-3Ј. These primers are designed to generate the full-length of the prf coding sequence (729 bp). For amplification of β-actin, the following primer pair was used: 5Ј-ATGGAT-GACGATATCGCT-3Ј and 5Ј-ATGAGGTAGTCTGTCAGGT-3Ј.
Northern blotting
A mouse multiple tissue blot (Clontech) was incubated with 32 P-labeled prf cDNA or β-actin cDNA at 65°C according to the manufacturer's instructions. 460 bp ApaLI-HincII fragment of prf cDNA was used as probe. The filter was washed with 0.5ϫSSC, 0.2% (w/v) SDS at 65°C for 30 min.
Transcriptional activation assay
Full-length cDNA of PU.1 (amino acids 1-272), Prf (amino acids 1-243), Prf (amino acids 44-243) or Prf (amino acids 93-243) was cloned separately into a plasmid vector pGBT9 (Clontech). A yeast strain HF7c was transformed with recombinant plasmid and incubated on the His -SD plate.
Results
Structure of the Prf protein
From the 5ϫ10 6 clones of the murine thymic cDNA library, three positive clones were isolated using the κE3Ј probe containing the PU.1-NF-EM5 binding region sequences (11) . The obtained clones were not identical and met all specific binding criteria. Nucleotide sequencing revealed that two of the clones code for the murine PU.1 protein. The third clone (#6-2) was found to encode a novel protein, containing an Ets DNA binding domain (Fig. 1A) . Using the #6-2 sequence as a probe, the cDNA encompassing the entire coding region was isolated from a murine splenic cDNA library. The largest clone contained a 1246 bp insert, corresponding to the major RNA transcript (1.5 kb) shown in the Northern blot (Fig. 4) . The complete nucleotide sequence of this clone is presented in Fig. 1(B) along with the predicted amino acid sequence.
The open reading frame begins at nucleotide 128 and ends at nucleotide 853. This cDNA can code for a novel protein of 243 amino acids with a calculated mol. wt of 29.6 kDa. Homology search in the Protein Identification Resource database revealed that the encoded protein was most homologous to the murine PU.1 and Spi-B proteins (15, 16) . We named this novel Ets family protein Prf, or PU.1-related factor. As shown in Fig. 2 , the Ets domain of Prf has high homology with those of other Ets family proteins: human Spi-B (61%), murine PU.1 (57%), murine Ets-1 (28%) (17) , murine GABA-α (33%) (18) , human Erg (31%) (19) , human SAP1B (32%) (20) , human Erf (30%) (21) and human TEL (36%) (22) . Judging from the predicted amino acids sequence, no functional domain was evident in the N-or C-terminus of Prf. When the Prf fragment spanning from amino acid residue 44 to 112 was fused to the GAL4-activation domain, the fusion protein did not show any binding to the bait DNA (data not shown). This indicated that Prf was binding to the bait DNA in the C-terminal region rather than in the N-terminal region, mostly likely with the Ets DNA binding domain.
Prf protein indeed binds to the PU.1 binding motif
To study in vitro binding, Prf protein was translated with the reticulocyte lysate as shown in Fig. 3(A) . A mobility of the slower-migrating protein (31 kDa) is consistent with the calculated mol wt of Prf. The faster-migrating protein (25 kDa) seems to be the product whose translation was aberrantly initiated at the third methionine of Prf. A mobility shift assay was performed with these products to determine whether the Prf protein indeed interacts with the PU.1 binding motif. Shifted bands were detected with the wild-type probe (PU.1-NF-EM5 binding sequences of κE3Ј) (Fig. 3B, lane 1 ), but not with the mutant probe in which the PU.1 binding sequence was changed from GAGGAA to TCTTCG (Fig. 3B, lane 6) . The two shifted bands were derived from the alternately translated Prf (31 and 25 kDa).
It has been reported that PU.1 recognizes the purinerich sequence in the regulatory region of various genes contributing to cell differentiation and development. We, therefore, studied whether the Prf protein could bind to the PU.1 binding motifs of other genes, e.g. Igλ 2-4 enhancer (24), cfes promoter (25) and FcγRI promoter (26) . It was found that all the PU.1 binding motifs so far tested were bound by the Prf protein. It should be mentioned that a PU.1 motif in the FcγRI promoter showed lower Prf-binding affinity (Fig. 3C) .
B cell-and stage-specific expression of Prf
Cell type specificity of Prf expression was studied by Northern blotting of poly(A) ϩ RNA isolated from various tissues. To avoid cross-hybridization to other Ets family genes, an ApaLIHincII fragment (460 bp) of prf cDNA, which lacks most of the sequence coding for the Ets domain, was used as a probe. As shown in Fig. 4 , three distinct bands of prf transcripts (1.5, 1.9 and 2.4 kb) were detected at high levels in the spleen. Low-level transcripts detected in the liver may be due to residual lymphoid cells in the tissue. Size differences of these transcripts probably represent alternative splicing or differential processing stages of a common precursor RNA. We have isolated and sequenced a Prf-positive cDNA clone from a murine splenic cDNA library, probably corresponding 
Relative expression levels are shown as Ϫ (negative), Ϯ (partially positive), ϩ (positive), based on our RT-PCR experiments for PU.1 and Prf, and published data by others for Spi-B (32).
to the 2.4 kb transcript of the prf gene. Since a stop codon is found upstream of the Ets domain coding region (data not shown), this transcript cannot encode a functional DNA binding protein.
To further study the cell-type specificity of prf expression, RT-PCR was performed with FACS-sorted cells from various lymphoid tissues. As shown in Fig. 5 , Prf is specifically expressed in B cells of bone marrow, spleen and thymus (Fig. 5A, lanes 2, 4, and 9 ). It is interesting that the Prf expression temporarily ceases in Ig ϩ immature B cells (Fig. 5A, lane 1) during the B cell development in bone marrow. We have studied the expression of prf in the FACSsorted pro-B cells (B220 ϩ , Ig -, HSA ϩ , CD43 ϩ ) and pre-B cells (B220 ϩ , Ig -, HSA ϩ , CD43 -) from bone marrow. The expression of prf was detected in the pre-B cells by RT-PCR, but not in pro-B cells (Fig. 5B) . In our sorting, the level of contamination of circulating B cells (B220 ϩ , Ig ϩ , HSA ϩ ) in the pre-B fraction was Ͻ1% and should not influence the RT-PCR experiment.
Prf does not show any transcriptional activation function in yeast When a fusion protein containing both the GAL4-DNA binding domain and transcriptional activation domain of a transcriptional factor is produced, the yeast strain HF7c can grow on the His -SD plates and express β-gal (Fig. 6) . Using this system, the transcriptional activation function was studied for the Prf protein. Although various regions of Prf were fused to the GAL4-DNA binding domain, no Prf regions showed transcriptional activation function (Fig. 6) . In contrast to Prf, the fusion protein of GAL4-DNA binding domain and PU.1 caused the yeast to grow on His -SD plates and expressed β-gal. Therefore, Prf may not function as a transcriptional activator.
Discussion
Using the Igκ E3Ј sequence as a probe, we have isolated a cDNA clone coding for a novel Ets family protein, Prf, which is highly homologous to PU.1 and Spi-B within the Ets DNA binding domain.
Ets family proteins are known to play key roles in the immune response and in the lymphoid cell development. For example, PU.1 is expressed in B lymphocytes, macrophages, granulocytes and monocytes (15, 27) , and is known to function as an important regulatory protein in hematopoiesis and in erythroleukemic transformation (28) (29) (30) . In contrast to PU.1, Spi-B expression is restricted to the lymphoid lineage, although Spi-B and PU.1 share many target genes in erythroid, myeloid and lymphoid cells. Their distinct patterns of expression may suggest that these genes have separate roles in regulating the immune system. PU.1 -/-mice showed various defects in T cell development as well as in the generation of B lymphocytes, monocytes and granulocytes (28) , while Spi-B -/-mice exhibited severe abnormalities in B cell functions and in the T cell-mediated humoral immunity (31) .
In comparison to the PU.1 and Spi-B proteins, Prf has two unique characteristics. One is an unusual pattern of expression, which is restricted in pre-B cells and mature B cells. Unlike Prf, PU.1 is expressed in all stages of B lineage cells and Spi-B is expressed in increasing amounts as B cells differentiate (32) ( Table 1 ). The other interesting feature is that Prf has no transcriptional activation function. Although Prf shares many target genes with PU.1 and Spi-B, its mode of action appears to be totally different. Both PU.1 and Spi-B act in a positive manner to activate various genes in the immune system. However, Prf may not be able to function by itself, because it lacks transcriptional activity. It is possible that Prf acts on the target genes as an antagonist against PU.1 or Spi-B. Prf may function in a similar manner as Erf, another Ets family protein, known to act as a repressor for the Ets-2 by competitive binding to the promoter (21, 33) . Erf is expressed ubiquitously and has an Ets DNA binding domain at the N-terminus and a repressor domain at the C-terminus. It can antagonize the activities of other Ets family proteins that act as positive transcriptional regulators. Although there is no significant homology between Prf and Erf, other than the Ets DNA binding domain, it is tempting to assume that Prf may function as a negative regulator, like Erf, during the development of B cells.
If Prf works as an antagonist against PU.1 or Spi-B, it will be interesting to study why the expression of Prf is temporally regulated during the B cell development in bone marrow. One intriguing possibility is that Prf may negatively regulate the stage-specific rearrangement of the Igκ light chain gene. It is also possible that Prf is involved in the negative selection of autoreactive immature B cells or in the homing of B cells from bone marrow to peripheral lymphoid tissue. We are currently in the process of producing prf -/-mutant mice. If such knockout mice are generated, they will hopefully establish the physiological roles of the Prf protein.
Abbreviations κE3Ј
Igκ 3Ј enhancer PE phycoerythrin APC allophycocyanin
Note added in proof
After the submission of our manuscript, Bemark et al. (J. Biol. Chem. 274:10259) reported the spi-C gene whose sequence is basically the same as our prf.
